Comparison between Warfarin Dose with Duration Achieving Target INR in Patient with CHF and Atrial Fibrillation

Article Sidebar

PDF (Bahasa Indonesia)
Published: Jul 12, 2016
DOI: https://doi.org/10.29208/jsfk.2016.2.2.67
Keywords:
Warfarin, INR, CHF, AF

Main Article Content

Tiara Tri Agustini
STIFAR Riau, Indonesia
Helmi Arifin
Faculty of Pharmacy, Andalas University, Indonesia
Akmal M. Hanif
Faculty of Pharmacy, Andalas University, Indonesia

Abstract

A study of comparison between warfarin dose with achieving target INR in patients with CHF and atrial fibrillation at RSUP. DR. M. Djamil Padang has been investigated. This study analyzed using one-way ANOVA and if the result is significant then followed by post hoc test. Of the total 27 patients, all the patients suffering from CHF and 11 patients suffering from hypertension. There were 15 patients aged <60 years, 11 patients aged between 60-74 years, and 1 patient aged ≥75 years. The number male and female patients are 11 and 16 people. The mean duration of achieving the target INR at dose 2 mg, dose (2 mg and 4 mg) and dose 5 mg are 38.22, 29.33, and 6.56 days. There is a significant difference in the mean duration of achieving the target INR in the dose group. 5 mg dose had a mean duration of achieving the target INR which significantly different compared to the other doses. 

A study of comparison betweenwarfarin dose with achieving target INR in patients with CHF and atrial fibrillation at RSUP. DR. M. Djamil Padang has been investigated. This study analyzed using one-way ANOVA and if the result is significant then followed by post hoc test. Of the total 27 patients,all the patients suffering fromCHF and11 patients suffering from hypertension. There were 15 patients aged <60 years, 11 patients aged between 60-74 years, and 1 patient aged ≥75 years. The number male and female patients are11 and 16 people. The mean duration of achieving the target INR at dose 2 mg, dose (2 mg and 4 mg) and dose 5 mg are 38.22, 29.33, and 6.56 days. There is a significant difference in the mean duration of achieving the target INR in the dose group. 5 mg dose had a mean duration of achieving the target INRwhich significantly different compared to the other doses.

Article Details

How to Cite
Agustini, T. T., Arifin, H., & Hanif, A. M. (2016). Comparison between Warfarin Dose with Duration Achieving Target INR in Patient with CHF and Atrial Fibrillation. Jurnal Sains Farmasi & Klinis, 2(2), 162–170. https://doi.org/10.29208/jsfk.2016.2.2.67
Issue
Vol. 2 No. 2 (2016): J Sains Farm Klin 2(2), Mei 2016
Section
Research Articles

The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.

References

Altmann, D. R., Kubne, M., Sticherling, C., Osswald, S., & Schaer, B. A. (2010). Use of the CHADS2 risk score to guide antithrombotic treatment in patients with atrial fibrillation-room for improvement. SWISS MED WKLY, 140(5-6), 73-77.

Camm, A., Kirchhof, P., Lip, G., Schotten, U., Savelieva, I., Ernst, S., . . . Rutten, F. (2010). Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 31, 2369-2429.

Morgan, C. L., McEwan, P., Tukiendorf, A., Robinson, P. A., Clemens, A., & Plumb, J. M. (2009). Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. Thrombosis Research, 124, 37-41.

Touchette, D. R., Mcguinness, M. E., Stoner, S., Shute, D., Edwards, J. M., & Ketchum, K. (2008, Jan-Mar). Improving outpatient warfarin use for hospitalized patients with atrial fibrillation. Pharmacy Practice, 6(1), 43-50.

Cabral, K. P., Ansell, J., & Hylek, E. M. (2011). Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost, 9, 441-449.

Homma, S., Thompson, J. L. P., Pullicino, P. M., Levin, B., Freudenberger, R. S., Teerlink, J. R., ... Buchsbaum, R. (2012). Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med, 366, 1859-69.

Dahlan, M. S. (2011). Statistik untuk Kedokteran dan Kesehatan (edisi 5). Jakarta: Salemba Medika.

Fuster, V., Ryden, L., Asinger, R., Cannom, D., Crijns, H., Frye, R., . . . Torbicki, A. (2001). ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol, 38, 1266i-lxx.

Gogna, A., & Arun, S. (2005). Oral anticoagulation in clinical practice. JIACM, 6(1), 53-66.

Sukandar, E., Andrajati, R., Sigit, J., Adnyana, K., Setiadi, A., & Kusnandar. (2008). ISO Farmakoterapi. Jakarta: PT. ISFI Penerbitan.

Veitch, A. M., Baglin, T. P., Gershlick, A. H., Harnden, S. M., Tighe, R., & Cairns, S. (2008). Guidelines for the management of anticoagulant and antiplatelet therapy In patients undergoing endoscopic procedures. Gut, 57, 1322-1329.

Shargel, L., Wu-Pong, S., & Yu, A. B. (2005). Applied Biopharmaceutics and Pharmacokinetics (5th Ed.). United States of America: The McGraw-Hill Companies.

Use of INR for monitoring warfarin treatment. (2010, November). Best Tests, 14-20.

Teklay, G., Shiferaw, N., Legesse, B., & Bekele, M. (2014). Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thrombosis Journal, 12, 20.